Brief: Orchard Therapeutics Receives Positive CHMP Opinion For Libmeldy
16/10/2020 11:06
Oct 16 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS RECEIVES POSITIVE CHMP OPINION FOR
LIBMELDY™ FOR THE TREATMENT OF EARLY-ONSET METACHROMATIC
LEUKODYSTROPHY (MLD)
* ORCHARD THERAPEUTICS PLC - ONE-TIME TREATMENT WITH
LIBMELDY HAS
BEEN SHOWN TO PRESERVE COGNITIVE AND MOTOR FUNCTION IN MOST
PATIENTS
* ORCHARD THERAPEUTICS PLC - A FINAL DECISION BY EC FOR
LIBMELDY
IS ANTICIPATED BEFORE END OF 2020
Source text for Eikon: ID:nGNX4GzvHN
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln